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The skin actively contributes to host defense by mounting an innate immune response that includes the production
of antimicrobial peptides. These peptides, which include but are not limited to the cathelicidin and defensin gene
families, provide rapid, broad-spectrum defense against infection by acting as natural antibiotics and by partic-
ipating in host cell processes involved in immune defense. This review discusses the biology and clinical relevance
of antimicrobial peptides expressed in the skin. The importance of the epithelial contribution to host immunity
is evident, as alterations in antimicrobial peptide expression have been associated with various pathologic
processes.
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Antimicrobial peptides are predominantly small cationic po-
lypeptides that are classified together due to their capacity
to inhibit the growth of microbes. As effectors of innate im-
munity, antimicrobial peptides directly kill a broad spectrum
of bacteria, fungi, and viruses. In addition, these peptides
modify the local inflammatory response and activate mech-
anisms of cellular and adaptive immunity. Cathelicidins and
defensins comprise the major families of antimicrobial pep-
tides in the skin, although other cutaneous peptides, such
as proteinase inhibitors, chemokines, and neuropeptides,
also demonstrate antimicrobial activity. Together, these
multifunctional antimicrobial peptides play an important
role in skin immune defense and disease pathogenesis.
Antimicrobial Peptides in the Skin:
Biological Relevance
Antimicrobial peptides, which are synthesized in the skin at
sites of potential microbial entry, provide a soluble barrier
that acts as an impediment to infection. In the case of in-
fection or injury, antimicrobial peptide expression in the skin
is upregulated due to increased synthesis by keratinocytes
and deposition from degranulation of recruited neutrophils.
Constitutive and inducible expression of human cathelicidin
(hCAP18/LL-37), as well as human b-defensins 1, 2, and 3
(hBD-1, hBD-2, hBD-3), have been observed in epidermal
keratinocytes (Frohm et al, 1997; Dorschner et al, 2001;
Harder et al, 2001).
Although antimicrobial peptides clearly demonstrate
in vitro antimicrobial activity, studies have shown that many
such peptides, including cathelicidins and defensins, are
inactivated by physiological salt concentrations (Goldman
et al, 1997). It is important to note that most antimicrobial
activity assays have been performed under non-physiolog-
ical conditions, using bacterial growth media rather than
a culture environment that closely resembles mammalian
skin. In fact, a recent study has shown that mammalian
skin contains an essential antimicrobial-enhancing factor
that renders bacteria susceptible to cathelicidin in vitro,
despite the presence of physiological salt and serum (Dors-
chner et al, 2004). The in vivo importance of antimicrobial
peptides in the physiological environment is further high-
lighted by the laboratory animal models and human skin
diseases that are discussed below.
Cathelicidins Cathelicidins are characterized by an N-ter-
minal signal peptide, a highly conserved cathelin domain
and a structurally variable cationic antimicrobial peptide at
the C-terminus. The cathelin domain functions as both a
protease inhibitor and as an antimicrobial peptide in hu-
mans (Zaiou et al, 2003). Mature cathelicidin peptides show
rapid, potent, and broad-spectrum antimicrobial activity
and have been implicated in various immunomodulatory
functions (Koczulla et al, 2003). Humans and mice have only
one cathelicidin gene, whereas other mammals, like pigs
and cattle, possess a variety of cathelicidin genes.
Human cathelicidin, LL-37, assumes an a-helical struc-
ture in solutions with ion compositions similar to human
plasma, interstitial fluid, or intracellular fluid. Processing of
LL-37 from the cathelicidin precursor is essential for acti-
vation of its antimicrobial activity and is accomplished by
neutrophil proteases such as proteinase 3 (Sorensen et al,
2001). LL-37 expression in squamous epithelia is differen-
tially regulated in several inflammatory conditions (Frohm
et al, 1997; Dorschner et al, 2001). LL-37 is produced in
eccrine structures, where it is secreted and processed in
sweat, suggesting a further barrier function against topical
skin infection (Murakami et al, 2004). In addition, LL-37 is
produced by mast cells and recruits mast cells (Di Nardo
et al, 2003), thereby participating in innate immunity both by
direct antimicrobial activity and by recruitment of cellular
defenses. LL-37 production is upregulated in neonatal skin,Abbreviation: hBD, human b-defensin
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where it may compensate for the developmental immaturity
of adaptive immune responses (Dorschner et al, 2003). A
true immunomodulatory effector molecule, LL-37 has direct
antimicrobial activity, acts synergistically with other antimi-
crobial peptides, functions as a chemoattractant for ne-
utrophils, monocytes and T cells, and stimulates endothelial
cell proliferation by binding to formyl peptide receptor-like 1
(FPRL-1) (Koczulla et al, 2003). As illustrated in Fig 1, the
multilayered expression and multifunctionality of cathelici-
din in the skin present a formidable innate defense system
against infection.
Studies of animal models have provided direct evidence
that cathelicidins are important components of host innate
immune defense (Nizet et al, 2001). For example, mice har-
boring a disruption of their single cathelicidin gene are un-
able to control Group A Streptococcus infection (Nizet et al,
2001). Pig wounds inhibited from processing porcine cat-
helicidins to their active peptide form also show increased
susceptibility to infection (Cole et al, 2001b).
Defensins Defensins contain six cysteine residues that
form characteristic disulfide bridges. Disulfide bridge align-
ment and molecular structure separate this major antimi-
crobial peptide family into a-, b-, and y-defensins. Distantly
related peptides are found in insects and plants. Mamma-
lian defensins exhibit antimicrobial activity against bacteria,
fungi, and enveloped viruses.
a-Defensins contain three disulfide bridges in a 1–6, 2–4,
3–5 alignment. Human neutrophils express four a-defensins,
which are also referred to as human neutrophil peptides 1
through 4 (HNP-1 to -4) (Harwig et al, 1994). Human de-
fensins 5 and 6 (HD-5 and -6) are abundantly expressed as
propeptides in Paneth cells of small intestinal crypts and in
epithelial cells of the female urogenital tract. In humans,
defensins are stored in azurophil granules of neutrophils as
fully processed, mature peptides. Like cathelicidins, a-de-
fensins affect both microbes and the host. For example,
HNP-1, -2, and -3 upregulate tumor necrosis factor alpha
(TNF-a) and IL-1 in human monocytes that have been ac-
tivated by bacteria; these peptides also reduce the expres-
sion of the adhesion molecule VCAM-1 in endothelial cells
activated by TNF-a (Chaly et al, 2000).
b-Defensins contain three disulfide bridges that are
spaced in a 1–5, 2–4, 3–6 pattern. The four best-known
human b-defensins, hBD-1 to -4, have been identified in
various cell types, including epithelial and peripheral blood
mononuclear cells (Harder et al, 2001; Fang et al, 2003; Liu
et al, 2003). hBD-1 is constitutively expressed in epithelia,
whereas hBD-2 is highly upregulated in inflamed skin. hBD-
3, which was purified from human psoriatic scales and cal-
luses (Harder et al, 2001), is inducible in a variety of tissues.
Recent genomic analysis suggests that many b-defensins
have yet to be discovered, although several have recently
been identified through novel computational gene discovery
strategies (Schutte et al, 2002).
b-Defensins have broad-spectrum antimicrobial activity
and additional immune-related cellular functions. For ex-
ample, hBD-2 binds to CCR6 and is chemotactic for im-
mature dendritic cells and memory T cells (Yang et al, 1999).
hBD-2 also promotes histamine release and prostaglandin
D2 production in mast cells, suggesting a potential immuno-
therapeutic role as a vaccine adjuvant to enhance antibody
production (Befus et al, 1999). hBD-2 is virtually absent in
normal skin and its expression in human keratinocytes
requires stimulation by cytokines or bacteria (Liu et al,
2003). The upregulation of hBD-2 by keratinocytes illus-
trates the important role that defensins play in host defense
against cutaneous pathogens.
Figure 1
Cathelicidins are strategically expres-
sed and contribute multiple functions
to skin defense. The human cathelicidin
precursor protein hCAP18 is expressed
by several cell types in the skin including
keratinocytes, neutrophils, eccrine ducts,
and mast cells. Cathelicidins are proc-
essed to active peptides such as LL-37 in
neutrophils and more potent peptides in
sweat. These peptides have been best
characterized as natural antibiotics, killing
a variety of bacterial, fungal, and viral pa-
thogens. Other functions include chemo-
tactic and angiogenic behaviors, and an
ability to modify fibroblast proteoglycan
synthesis. The N-terminal cathelin-like
domain of the hCAP18 precursor protein
contains both antimicrobial and protein-
ase inhibitor activity.
10 BRAFF ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Other antimicrobial peptides and proteins Whereas the
cathelicidin and defensin families are best known for their
antimicrobial properties, many peptides that have been
ascribed alternate functions in the skin also demonstrate
antimicrobial activity, including proteinase inhibitors, che-
mokines, and neuropeptides, to name a few (Table I). Inter-
estingly, the dependence of the antimicrobial activity of
these peptides on their originally described function varies,
and no clear trend is observed. For example, the antimi-
crobial activity of ECP/RNase 3 does not require ribonuc-
lease activity, which is essential for the antiviral activity of
both ECP/RNase 3 and EDN/RNase 2 (Domachowske et al,
1998a, b). P-cystatin a inhibits bacterial proteinase activity
as a mechanism of microbial growth inhibition (Takahashi
et al, 1994), whereas cystatin C antimicrobial activity does
not depend on its ability to inhibit bacterial proteinases
(Blankenvoorde et al, 1998). The antiviral activity of cystatin
C, however, appears to reside in the proteinase-binding
domain. Calprotectin contains zinc-binding sites and inhib-
its microbial growth through competition for metals (Sohnle
et al, 2000), whereas NGAL interferes with bacterial iron
acquisition (Goetz et al, 2002). a-MSH contains a tripeptide
that is important for antipyretic, anti-inflammatory and an-
timicrobial activity, while sequences involved in learning and
memory are not necessary for antimicrobial activity (Cutuli
Table I. Mammalian peptides and proteins relevant to skin with
antimicrobial activity (AMP)a
References
AMP identified in resident cells
Cathelicidins Frohm et al (1997),
Marchini et al (2002)
b-Defensins Harder et al (2001),
Liu et al (2003)
Bactericidal/permeability-
increasing protein (BPI)
Takahashi et al (2004)
Lactoferrin Cumberbatch et al (2000)
Lysozyme Marchini et al (2002)
Dermcidin Schittek et al (2001),
Murakami et al (2004)
RNase 7 Harder and Schroder (2002)
AMP identified in infiltrating cells
Cathelicidins Gallo et al (1994),
Marchini et al (2002)
a-Defensins Harwig et al (1994)
Lactoferrin Caccavo et al (2002)
Granulysin Stenger et al (1998)
Perforin Stenger et al (1998)
Eosinophil cationic protein (ECP)/
RNase 3
Domachowske et al (1998a)
Eosinophil-derived neurotoxin
(EDN)/RNase 2
Domachowske et al (1998b)
Regulated upon activation, normal
T cells expressed and secreted
(RANTES)
Tang et al (2002)
Table I. Continued
References
Platelet factor 4 (PF-4) Tang et al (2002)
Connective tissue activating
peptide 3 (CTAP-3)
Tang et al (2002)
Platelet basic protein Tang et al (2002)
Thymosin b-4 (Tb-4) Tang et al (2002)
Fibrinopeptide B (FP-B) Tang et al (2002)
Fibrinopeptide A (FP-A) Tang et al (2002)
AMP identified as proteinase inhibitors
hCAP18/LL-37 prosequence
(cathelin-like domain)
Zaiou et al (2003)
Secretory leukocyte proteinase
inhibitor (SLPI)/Antileukoprotease
Wingens et al (1998)
Elafin/skin-derived
antileukoprotease (SKALP)
Simpson et al (1999),
Meyer-Hoffert et al (2003)
P-cystatin a Takahashi et al (1994)
Cystatin C Blankenvoorde et al (1998)
AMP identified as chemokines
Psoriasin Glaser et al (2001)
Monokine induced by IFN-g (MIG/
CXCL9)
Cole et al (2001a)
IFN-g-inducible protein of 10 kDa
(IP-10/CXCL10)
Cole et al (2001a)
IFN-g-inducible T cell a
chemoattractant (I-TAC/CXCL11)
Cole et al (2001a)
Antimicrobial peptides identified as neuropeptides
a-Melanocyte stimulating hormone
(a-MSH)
Cutuli et al (2000)
Substance P Kowalska et al (2002)
Bradykinin Kowalska et al (2002)
Neurotensin Kowalska et al (2002)
Vasostatin-1 and chromofungin
(chromogranin A)
Tasiemski et al (2002)
Secretolytin (chromogranin B) Tasiemski et al (2002)
Enkelytin and peptide B
(proenkephalin A)
Tasiemski et al (2002)
Ubiquitin Kieffer et al (2003)
Neuropeptide Y Lambert et al (2002)
Polypeptide YY/skin-polypeptide
YY
Lambert et al (2002)
Adrenomedullin Allaker et al (1999)
AMP identified based on other functions
Hemoglobin-derived peptides Parish et al (2001)
Calprotectin (MRP8/MRP14)/
calgranulin A/B
Sohnle et al (2000)
Neutrophil gelatinase-associated
lipocalin (NGAL)
Goetz et al (2002)
Epidermal H1 histones Kashima (1991)
Myeloperoxidase Rosen and Michel (1997)
aReferences limited due to space restrictions.
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et al, 2000). Lactoferrin antimicrobial activity does not de-
pend on antitumor activity (Yang et al, 2004) and the an-
tiproteinase and antimicrobial activity of elafin/SKALP
reside in separate domains (Simpson et al, 1999). Chemo-
tactic and antimicrobial activities are intertwined in MIG/
CXCL9, IP-10/CXCL10, and I-TAC/CXCL11, which are
structurally related to defensins in size, cationic charge,
and disulfide bonding (Cole et al, 2001a). Similarly, the
structure of substance P resembles that of Arg/Pro-rich
bactericidal peptides, suggesting that substance P antimi-
crobial activity is linked to its ability to modulate the nervous
and immune systems (Kowalska et al, 2002).
Antimicrobial Peptides in the Skin: Clinical
Relevance
Differential expression of antimicrobial peptides appears to
play a role in the susceptibility of patients with chronic in-
flammatory skin disorders to infectious complications. For
example, LL-37 is induced in human keratinocytes during
psoriasis, lupus erythematosus and contact dermatitis
(Frohm et al, 1997). hBD-2 and hBD-3 are also upregulat-
ed in keratinocytes of inflamed psoriatic lesions (Harder
et al, 2001; Nomura et al, 2003). The increased expression
of antimicrobial peptides in psoriasis correlates with a low
rate of secondary infection. In contrast, the expression of
LL-37 and hBD-2 is not upregulated in individuals with
atopic dermatitis, who are highly susceptible to bacterial
and viral infections (Ong et al, 2002). The differences in an-
timicrobial peptide expression between these two disorders
gain immunological relevance in light of the antimicrobial
activity of LL-37 against S. pyogenes (Dorschner et al, 2001)
and its synergistic activity with b-defensins against S. au-
reus (Ong et al, 2002), a leading agent of human skin
infections.
LL-37 expression is upregulated in inflammatory skin le-
sions of erythema toxicum neonatorum and immunolocal-
izes within CD15-expressing neutrophils, EG-2-expressing
eosinophils, and CD1a-expressing dendritic cells (Marchini
et al, 2002). LL-37 is also induced within the epidermis
during development of verruca vulgaris and condyloma
accuminata, suggesting that it represents a component of
the innate immune response to papillomavirus infection
(Conner et al, 2002). Both hBD-1 and hBD-2 are upregulated
in the lesions of acne vulgaris and may therefore be involved
in the pathogenesis or resolution of this condition (Philpott,
2003). In addition, hBD-2 and the HNP are abundant in le-
sions of superficial folliculitis, a common skin disease char-
acterized by inflammation of the hair follicle and infection
with S. aureus (Oono et al, 2003). These studies indicate
potential roles for antimicrobial peptides in host immune
defense against skin infection.
Cathelicidin is produced at high levels in the skin after
wounding (Dorschner et al, 2001) and is strongly expressed
in healing skin epithelium (Heilborn et al, 2003). After cuta-
neous wounding, growth factors stimulate tissue regener-
ation until the physical barrier protecting the skin from
microbial infections has been re-established. Growth fac-
tors important in skin wound healing, such as insulin-like
growth factor-1 (IGF-1) and transforming growth factor-a
(TGF-a, induce the expression of cathelicidins and defen-
sins in human keratinocytes (Sorensen et al, 2003). LL-37
antibodies inhibit post-wounding re-epithelialization in a
concentration-dependent manner and cathelicidin expres-
sion is low or absent in chronic ulcers (Heilborn et al, 2003).
The ability of LL-37 to induce angiogenesis further high-
lights the importance of cathelicidin in wound healing and
tissue repair (Koczulla et al, 2003). In addition, the expres-
sion of hBD-2 is dramatically decreased in burn wounds
and blister fluid from partial thickness burns (Ortega et al,
2000), providing evidence that innate immune defects may
contribute to the risk of burn wound infection and sepsis.
Conclusion
Skin innate immune defense function is greatly enhanced by
a soluble antimicrobial peptide barrier that is activated
when physical barriers fail to prevent microbial entry. Even
under resting conditions, low levels of antimicrobial pep-
tides are synthesized at sites of potential microbial entry
into the skin and provide a further impediment to infection.
After injury, antimicrobial peptide levels in the skin rise rap-
idly due to increased synthesis by keratinocytes and dep-
osition from degranulation of recruited neutrophils. The
chemoattractant properties of cathelicidins and defensins
may further amplify this process through their functional in-
teractions with leukocyte surface receptors. The growing
number of multifunctional peptides found to inhibit microbial
growth further expands the mammalian antimicrobial arse-
nal, demonstrating that the host antimicrobial peptide def-
ense system acts both directly and indirectly to prevent
cutaneous infection.
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